ReviewCurrent neuropharmacology2019
Immune-mediated Cerebellar Ataxias: Practical Guidelines and Therapeutic Challenges.
Review in Current neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Cell-Based Therapies for Spinocerebellar Degenerations: A Systematic Review of Human Clinical Evidence.Cerebellum (London, England) · 2026Pooled it
- Celiac Disease and the Nervous System: A Comprehensive Overview of Neurological Manifestations and Underlying Mechanisms.Neuromolecular medicine · 2026Review
- Relapsing Seronegative Immune-Mediated Cerebellar Ataxia with Evolving Intrathecal Immune Activation and Rituximab Consolidation in a Toddler: A Case Report.Cerebellum (London, England) · 2026Article
- Synaptophysin autoantibodies mediate synaptic dysfunction in cerebellar ataxia.Cell reports. Medicine · 2026Article
- Paraneoplastic neurologic syndrome in a 65-year-old woman with small cell lung cancer.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Celiac disease as a model of gut-brain autoimmunity: from gluten exposure to neuropsychiatric manifestations.Frontiers in pediatrics · 2026Review
- Neuroimmune mechanisms of the cerebellum-brainstem network in autoimmune encephalitis and related neuroimmune disorders: antibody targets, selective vulnerability, and translational opportunities.Frontiers in immunology · 2026Review
- Non-paraneoplastic autoimmune cerebellar ataxia with anti-ATP1A3 antibodies: a case report and literature review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- FDG-PET in Autoimmune Cerebellar Ataxia: Clinical Correlation and Diagnostic Superiority Over MRI.Cerebellum (London, England) · 2025Article
- Autoimmune cerebellar ataxia associated with anti-SEZ6L2 antibody: report of three cases.Journal of neurology · 2025Article
- Autoimmune cerebellar ataxia with anti-Homer3 antibodies associated with herpesvirus infection: a case report and literature review.Frontiers in immunology · 2025Review
- The utilization of efgartigimod in the treatment of acute cerebellar ataxia: a case report.Frontiers in immunology · 2025Article
- Clinical features of autoimmune cerebellar ataxia related to neuronal antibodies.Frontiers in immunology · 2025Article
- A Case Series of Anti-Metabotropic Glutamate Receptor 2 Antibody-Related Diseases with Distinct Neurological Involvement.ImmunoTargets and therapy · 2025Article
- Refractory Celiac Disease Causing Cavitating Mesenteric Lymph Node Syndrome and Celiac Disease Associated Central Nervous System Demyelinating Disorder.Gastro hep advances · 2025Article
- Glutamic Acid Decarboxylase 65 Antibody-associated Epilepsy and Diplopia: Two Case Reports with Literature Review.Cerebellum (London, England) · 2024Review
- COVID-19-Associated Cerebellar Ataxia: A Case Series.Cerebellum (London, England) · 2024Article
- Development of a novel nomogram for predicting prognosis of North Chinese with autoimmune cerebellar ataxia.Annals of medicine · 2024Article
- Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms.Journal of neurology · 2024Review
- Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
Abstract
Immune-mediated cerebellar ataxias (IMCAs), a clinical entity reported for the first time in the 1980s, include gluten ataxia (GA), paraneoplastic cerebellar degenerations (PCDs), antiglutamate decarboxylase 65 (GAD) antibody-associated cerebellar ataxia, post-infectious cerebellitis, and opsoclonus myoclonus syndrome (OMS). These IMCAs share common features with regard to therapeutic approaches. When certain factors trigger immune processes, elimination of the antigen( s) becomes a priority: e.g., gluten-free diet in GA and surgical excision of the primary tumor in PCDs. Furthermore, various immunotherapeutic modalities (e.g., steroids, immunoglobulins, plasmapheresis, immunosuppressants, rituximab) should be considered alone or in combination to prevent the progression of the IMCAs. There is no evidence of significant differences in terms of response and prognosis among the various types of immunotherapies. Treatment introduced at an early stage, when CAs or cerebellar atrophy is mild, is associated with better prognosis. Preservation of the "cerebellar reserve" is necessary for the improvement of CAs and resilience of the cerebellar networks. In this regard, we emphasize the therapeutic principle of "Time is Cerebellum" in IMCAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.